CDEK
← All organizations

Recordati

For profitContributed to NME

Also known as: Casen Recordati S.L. | Laboratoires Bouchara-Recordati | Recordati AG | RECORDATI GROUP | Recordati Industria Chimica e Farmaceutica S.p.A. | Recordati Pharmaceutical company | RECORDATI RARE | Recordati Rare Diseases | Recordati Rare Diseases, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

May 1, 2006

First marketed drug

Dec 31, 1943

First NDA

Apr 22, 1957

Last known activity

Aug 31, 2026

Timeline

1920s

  1. Jan 1, 1926

    Recordati— Founded

1970s

  1. Jun 23, 1972

    clorazepate— NDA Organization

1990s

  1. Jan 1, 1999

    Laboratoires Doms Adrian— Acquired

2000s

  1. Jan 1, 2000

    Bouchara— Acquired

  2. Jan 1, 2005

    Merckle— Acquired

  3. Jan 1, 2006

    Grupo Jaba— Acquired

  4. Jan 1, 2007

    Orphan EuropeOrphan Europe— Acquired

  5. Jan 1, 2008

    FIC Medical— Acquired

  6. Jan 1, 2008

    Yeni Ilaç ve Hammaddeleri— Acquired

  7. Jan 1, 2009

    Herbacos-Bofarma— Acquired

2010s

  1. Jan 1, 2010

    ArtMed International— Acquired

  2. Jan 1, 2011

    Frick Ilac— Acquired

  3. Jan 1, 2012

    Farma-Projekt— Acquired

  4. Dec 14, 2012

    pasireotide— Marketing Organization

  5. Dec 14, 2012

    pasireotide— NDA Secondary Org

  6. Jan 1, 2013

    Laboratorios Casen Fleet— Acquired

  7. Jan 1, 2013

    Opalia Pharma SA— Acquired

Drugs by trial phase (30 distinct, 31 trials)

Phase 1 (1 own, 2 via acquisition)

Other trials (2 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (15)

Subsidiaries (13 direct, 13 total across the full acquisition tree)

Recent trials (26)

Details

Founded
Correggio, IT Jan 1, 1926
First NDA
Apr 22, 1957
Last known activity
Aug 31, 2026

Designations held

  • Orphan drug
  • Priority review

Notes

Acquired by CVC Capital